DGAP-News
Visunex Medical Systems Receives CE Marking for the PanoCam LT System
DGAP-News: Visunex Medical Systems / Key word(s): Miscellaneous
Visunex Medical Systems Receives CE Marking for the PanoCam LT System
02.04.2016 / 00:43
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Visunex Medical Systems Receives CE Marking for the PanoCam LT System
02.04.2016 / 00:43
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
FREMONT, CA --(Marketwired - April 01, 2016) - Visunex Medical
Systems, Inc. today announced that it has received CE Mark for
the PANOCAM LT Wide-field Imaging System. PanoCam LT is a
compact, wireless imaging system that is designed to detect a
number of external, anterior, and posterior segment vision
disorders in premature and newborn babies. It can also be used
for general ophthalmic imaging and eye disease inspection in
children up to 6 years old.
'Obtaining the CE mark for PanoCam LT is an important milestone
for Visunex, as it allows the commercialization of this product
in the European Union and several other countries,' stated Dr.
Wei Su, CEO of Visunex Medical Systems. The CE mark indicates
that the system has met all the requirements of the European
Medical Devices Directive, including safety and performance.
Clinicians in countries requiring CE Mark now have access to the
world's first completely wireless hardware, software and
telemedicine solution for identifying vision disorders in
newborns.
Each year an estimated 130 million babies are born globally. At
birth, newborns are subject to a number of mandatory tests which
include hearing screening and bilirubin testing. Although vision
screening is not currently provided as a standard of care in most
neonatal centers, recent clinical data suggests that vision
disorders may affect between 10 and 20 percent of all newborns.
Early research conducted in Asia, Brazil and the United States
suggests that 1 in 70 children born may have some form of vision
disorder.
While many visual problems may be transient, a growing number of
clinicians believe that screening newborns may provide early
detection of vision disorders such as retinal hemorrhages, which
may be a precursor to amblyopia. This serious affliction may have
long-term effects on vision and can even permanently impair
vision throughout adulthood. Early detection of retinal
hemorrhages as well as many other disorders can lead to early
therapeutic intervention, which may prevent vision loss.
About the Company: Visunex Medical Systems is a pioneer in
developing the most advanced technology and information systems
for preserving the vision of children around the world. Our
products maximize quality and efficiency in the flow of ocular
images and patient data. Based in Fremont, California, the
company continues to innovate and deliver superior products and
services to enhance global vision. For more information, please
visit www.visunexmedical.com
Company contact:
Shalini Swamy
Director of Marketing
Phone: 510-996-4720 X412
shalini.swamy@visunexusa.com
News Source: Marketwire
---------------------------------------------------------------------------
02.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Visunex Medical Systems
United States
End of News DGAP News Service
---------------------------------------------------------------------------
450779 02.04.2016
Systems, Inc. today announced that it has received CE Mark for
the PANOCAM LT Wide-field Imaging System. PanoCam LT is a
compact, wireless imaging system that is designed to detect a
number of external, anterior, and posterior segment vision
disorders in premature and newborn babies. It can also be used
for general ophthalmic imaging and eye disease inspection in
children up to 6 years old.
'Obtaining the CE mark for PanoCam LT is an important milestone
for Visunex, as it allows the commercialization of this product
in the European Union and several other countries,' stated Dr.
Wei Su, CEO of Visunex Medical Systems. The CE mark indicates
that the system has met all the requirements of the European
Medical Devices Directive, including safety and performance.
Clinicians in countries requiring CE Mark now have access to the
world's first completely wireless hardware, software and
telemedicine solution for identifying vision disorders in
newborns.
Each year an estimated 130 million babies are born globally. At
birth, newborns are subject to a number of mandatory tests which
include hearing screening and bilirubin testing. Although vision
screening is not currently provided as a standard of care in most
neonatal centers, recent clinical data suggests that vision
disorders may affect between 10 and 20 percent of all newborns.
Early research conducted in Asia, Brazil and the United States
suggests that 1 in 70 children born may have some form of vision
disorder.
While many visual problems may be transient, a growing number of
clinicians believe that screening newborns may provide early
detection of vision disorders such as retinal hemorrhages, which
may be a precursor to amblyopia. This serious affliction may have
long-term effects on vision and can even permanently impair
vision throughout adulthood. Early detection of retinal
hemorrhages as well as many other disorders can lead to early
therapeutic intervention, which may prevent vision loss.
About the Company: Visunex Medical Systems is a pioneer in
developing the most advanced technology and information systems
for preserving the vision of children around the world. Our
products maximize quality and efficiency in the flow of ocular
images and patient data. Based in Fremont, California, the
company continues to innovate and deliver superior products and
services to enhance global vision. For more information, please
visit www.visunexmedical.com
Company contact:
Shalini Swamy
Director of Marketing
Phone: 510-996-4720 X412
shalini.swamy@visunexusa.com
News Source: Marketwire
---------------------------------------------------------------------------
02.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Visunex Medical Systems
United States
End of News DGAP News Service
---------------------------------------------------------------------------
450779 02.04.2016